The efficacy of TC-G 1008 in reducing acetylcholine (ACh) release, a key component of overactive bladder (OAB) treatment, is evidenced by reduced expression of both vesicular acetylcholine transporter (VAChT) and organic cation transporter 3 (OCT3). The gene discussed is SLC18A3; the disease is overactive bladder.